Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC—a systematic review and meta-analysis

Autor: Dafni, U., Soo, R.A., Peters, S., Tsourti, Z., Zygoura, P., Vervita, K., Han, J.-Y., De Castro, J., Coate, L., Früh, M., Hashemi, S.M.S., Nadal, E., Carcereny, E., Sala, M.A., Bernabé, R., Provencio, M., Cuffe, S., Roschitzki-Voser, H., Ruepp, B., Rosell, R., Stahel, R.A.

Publikováno v: In ESMO Open June 2022 7(3)

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

Autor: Sooy, R. A. Han, J. -Y. Dafni, U. Cho, B. C. Yeo, C. M. and Nadal, E. Carcereny, E. de Castro, J. Sala, M. A. and Bernabe, R. Coate, L. Provencio Pulla, M. Campelo, R. Garcia and Cuffe, S. Hashemi, S. M. S. Fruh, M. Massuti, B. and Garcia-Sanchez, J. Domine, M. Majem, M. Sanchez-Torres, J. -M. Britschgi, C. Pless, M. Dimopoulou, G. and Roschitzki-Voser, H. Ruepp, B. Rosell, R. Stahel, R. A. and Peters, S. ETOP 10-16 BOOSTER Collaborators

Background: While osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) is the standard treatment in patients with advanced non-small-cell lung cancer (NSCLC) with sensitising EGFR and acquired T790M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::0fd242c68cafda7025ac62c44a663f8b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3034424

VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial

Autor: Soo, R., Han, J-Y., Dimopoulou, G., Cho, B.C., Yeo, C.M., Nadal, E., Carcereny, E., de Castro, J., Sala, M.A., Bernabe, R., Coate, L., Provencio, M., Campelo, R. Garcia, Cuffe, S., Hashemi, S., Früh, M., Ruepp, B., Roschitzki-Voser, H., Stahel, R., Peters, S.

Publikováno v: In Annals of Oncology July 2021 32(7):942-944

16MO Clinical impact of plasma EGFR analysis: Results from the ETOP-BOOSTER randomized phase II trial

Autor: Soo, R.A., Dafni, U., Han, J-Y., Cho, B.C., Nadal, E., Yeo, C.M., Carcereny, E., de Castro, J., Gonzalez, M.A. Sala, Coate, L., Pulla, M. Provencio, Britschgi, C., Vagenknecht, P., Dimopoulou, G., Kammler, R., Finn, S.P., Peters, S., Stahel, R.A.

Publikováno v: In Journal of Thoracic Oncology April 2023 18(4) Supplement:S49-S50

Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial

Autor: Peters S, Stahel RA, Dafni U, Ponce Aix S, Massutí B, Gautschi O, Coate L, López Martín A, van Heemst R, Berghmans T, Meldgaard P, Cobo Dols M, Garde Noguera J, Curioni-Fontecedro A, Rauch D, Mark MT, Cuffe S, Biesma B, van Henten AMJ, Juan Vidal Ó, Palmero Sanchez R, Villa Guzmán JC, Collado Martin R, Peralta S, Insa A, Summers Y, Láng I, Horgan A, Ciardiello F, de Hosson S, Pieterman R, Groen HJM, van den Berg PM, Zielinski CC, Chittazhathu Kurian Kuruvilla Y, Gasca-Ruchti A, Kassapian M, Novello S, Torri V, Tsourti Z, Gregorc V, Smit EF, EMPHASIS-lung Collaborative Group

Publikováno v: JOURNAL OF THORACIC ONCOLOGY
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
Journal of Thoracic Oncology, 12(4), 752-762. International Association for the Study of Lung Cancer
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Peters, S, Stahel, R A, Dafni, U, Ponce Aix, S, Massutí, B, Gautschi, O, Coate, L, López Martín, A, van Heemst, R, Berghmans, T, Meldgaard, P, Cobo Dols, M, Garde Noguera, J, Curioni-Fontecedro, A, Rauch, D, Mark, M T, Cuffe, S, Biesma, B, van Henten, A M J, Juan Vidal, Ó, Palmero Sanchez, R, Villa Guzmán, J C, Collado Martin, R, Peralta, S, Insa, A, Summers, Y, Láng, I, Horgan, A, Ciardiello, F, de Hosson, S, Pieterman, R, Groen, H J M, van den Berg, P M, Zielinski, C C, Chittazhathu Kurian Kuruvilla, Y, Gasca-Ruchti, A, Kassapian, M, Novello, S, Torri, V, Tsourti, Z, Gregorc, V, Smit, E F & EMPHASIS-lung Collaborative Group 2017, ' Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non–Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial ', Journal of Thoracic Oncology, vol. 12, no. 4, pp. 752-762 . https://doi.org/10.1016/j.jtho.2016.12.017
Journal of Thoracic Oncology, 12(4), 752-762. ELSEVIER SCIENCE INC

Introduction: Docetaxel and erlotinib are registered second line treatments for wild-type EGFR NSCLC. Previous studies suggested a predictive value of the VeriStrat test in second line therapy of NSCLC, classifying patients as either VeriStrat good o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1d367d8bc33b24edc27d000909d5bd
https://pubmed.ncbi.nlm.nih.gov/28343541